Clinical trial / 2001
Oral curcumin up to 8,000 mg/day for 3 months was non-toxic and showed potential histologic improvement in some precancerous lesions.
A phase I trial evaluated oral curcumin taken for 3 months in 25 patients across five high-risk conditions, escalating doses up to 12,000 mg/day. No treatment-related toxicity occurred up to 8,000 mg/day (doses beyond this were unacceptable due to bulky volume), with average peak serum concentrations reaching 1.77 +/- 1.87 microM at 8,000 mg. Histologic improvement was observed in 1 of 2 resected bladder cancer patients, 2 of 7 oral leucoplakia patients, 1 of 6 intestinal metaplasia patients, 1 of 4 CIN patients, and 2 of 6 Bowen's disease patients, although frank malignancies developed in 1 CIN and 1 oral leucoplakia patient.
- Study type
- Phase I dose-escalation clinical trial
- Who was studied
- 25 patients with high-risk or pre-malignant lesions
- What was measured
- Toxicity, pharmacokinetics, and histologic changes in precancerous lesions
THE PAPER
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Anticancer Res, 2001.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.